

Data regarding the list price (LP) and dates of approval of the drugs

Table S I. Analysis of the evolution of the LP of the different generic Vinorelbine medicines approved in Spain with respect to the innovative drug.

Drug type & company	CIPM approval date	Marketing authorization date	CIPM LP (€/mg)*	Interval since 1st Gx approval by CIPM (years)	Price difference vs innovative price	Price difference vs 1st Gx approved by CIPM
Innovative (Pierre Fabre)	20/01/2001	01/07/1993	1.43	NA	NA	NA
Generic 1 (Actavis)	12/03/2009	04/11/2008	0.9	0	-37%	NA
Generic 2 (IPS Pharma)	29/11/2010	09/07/2010	0.69	1.7	-52%	-23%
Generic 3 (Sandoz)	30/06/2013	30/04/2009	0.63	4.3	-56%	-30%
Generic 4 (Accord)	28/02/2018	16/11/2007	0.63	9.0	-56%	-30%

* In the case of the innovative drug, the authorized LP at the time of marketing of the first generic drug is indicated.

Table S II. Analysis of the evolution of the LP of the different generic Paclitaxel medicines approved in Spain with respect to the innovative drug.

Drug type & company	CIPM approval date	Marketing authorization date	CIPM LP (€/mg)*	Interval since 1st Gx approval by CIPM (years)	Price difference vs innovative price	Price difference vs 1st Gx approved by CIPM
Innovador (BMS)	01/10/2006	01/11/1999	4.27	NA	NA	NA
Generic 1 (Merck)	08/11/2007	30/05/2007	1.87	0	-56%	NA
Generic 2 (GP-Pharm)	09/10/2008	05/05/2008	1.87	0.9	-56%	0%
Generic 3 (Stragen)	07/05/2009	15/12/2008	1.35	1.5	-68%	-28%
Generic 4 (Accord)	29/02/2012	27/10/2011	1.31	4.3	-69%	-30%
Generic 5 (Swan Pond)	30/06/2012	14/02/2012	1.31	4.6	-69%	-30%
Generic 6 (Fresenius)	31/07/2012	15/10/2010	1.31	4.7	-69%	-30%
Generic 7 (Cipla)	31/12/2015	09/10/2015	1.31	8.2	-69%	-30%

*1 In the case of the innovative drug, the most recent obtained (October 2006) is taken as LP.

*2 In the case of the innovative drug, the authorized LP at the time of marketing of the first generic is indicated.

Table S III. Analysis of the evolution of the LP of the different generic Capecitabine medicines approved in Spain with respect to the innovative drug.

Drug type & company	CIPM approval date	Marketing authorization date	CIPM LP (€/mg)*	Interval since 1st Gx approval by CIPM (years)	Price difference vs innovative price	Price difference vs 1st Gx approved by CIPM
Innovador (Roche)	26/05/2008	02/02/2001	0.0057	NA	NA	NA
Generic 1 (Actavis)	30/04/2013	21/01/2013	0.0035	0	-39%	NA
Generic 2 (Fresenius)	31/07/2013	25/03/2013	0.0023	0.3	-60%	-34%
Generic 3 (Kern)	30/11/2013	25/06/2012	0.0023	0.6	-60%	-34%
Generic 4 (Combino)	30/11/2013	17/09/2013	0.0023	0.6	-60%	-34%
Generic 5 (Sun)	31/12/2013	23/07/2013	0.0023	0.7	-60%	-34%
Generic 6 (Cipla)	31/03/2015	01/12/2014	0.0018	1.9	-68%	-49%
Generic 7 (Normon)	30/11/2015	28/07/2015	0.0018	2.6	-68%	-49%
Generic 8 (Labosuan)	29/02/2016	11/09/2015	0.0018	2.8	-68%	-49%
Generic 9 (Fair-Med)	30/04/2016	07/10/2015	0.0018	3.0	-68%	-49%

* In the case of the innovative drug, the authorized LP at the time of marketing of the first generic drug is indicated.

Table S IV. Analysis of the evolution of the LP of the different generic Imatinib medicines approved in Spain with respect to the innovative drug.

Drug type & company	CIPM approval date	Marketing authorization date	CIPM LP (€/mg)*	Interval since 1st Gx approval by CIPM (years)	Price difference vs innovative price	Price difference vs 1st Gx approved by CIPM
Innovative (Novartis)	25/05/2007	07/11/2001	0.20	NA	NA	NA
Generic 1 (Aurovitas)	30/06/2016	26/01/2016	0.12	0	-40%	NA
Generic 2 (Accord)	30/06/2016	28/03/2016	0.118	0.0	-40%	0%
Generic 3 (Sandoz)	30/07/2016	31/03/2016	0.118	0.1	-40%	0%
Generic 4 (Teva)	30/07/2016	01/06/2016	0.118	0.1	-40%	0%
Generic 5 (Ranbaxy)	31/10/2016	14/07/2015	0.118	0.3	-40%	0%
Generic 6 (Normon)	31/10/2016	05/07/2016	0.118	0.3	-40%	0%
Generic 7 (Ferrer)	30/11/2016	16/03/2015	0.118	0.4	-40%	0%
Generic 8 (Krka)	30/11/2016	19/09/2016	0.118	0.4	-40%	0%
Generic 9 (Cipla)	31/12/2016	29/09/2016	0.118	0.5	-40%	0%
Generic 10 (Kern)	31/12/2016	17/10/2016	0.118	0.5	-40%	0%
Generic 11 (Farmalider)	30/04/2017	11/03/2016	0.118	0.8	-40%	0%
Generic 12 (Fresenius)	30/04/2017	10/01/2017	0.118	0.8	-40%	0%
Generic 13 (Viso)	01/09/2017	26/01/2016	0.118	1.2	-40%	0%
Generic 14 (Reddy)	30/06/2019	27/07/2018	0.011	3.0	-94%	-91%
Generic 15 (Labosuan)	31/07/2019	01/03/2019	0.011	3.1	-94%	-91%
Generic 16 (Torbis)	31/01/2021	10/06/2020	0.006	4.6	-97%	-95%
Generic 17 (Qilu)	31/05/2021	26/01/2021	0.006	4.9	-97%	-95%

* In the case of the innovative drug, the authorized LP at the time of marketing of the first generic drug is indicated.

Table S V. Analysis of the evolution of the LP of the different generic Pemetrexed medicines approved in Spain with respect to the innovative drug.

Drug type & company	CIPM approval date	Marketing authorization date	CIPM LP (€/mg)*	Interval since 1st Gx approval by CIPM (years)	Price difference vs innovative price	Price difference vs 1st Gx approved by CIPM
Innovative (Lilly)	08/07/2008	20/09/2004	2.400	NA	NA	NA
Generic 1 (Sandoz)	30/04/2016	18/09/2015	1.440	0	-40%	NA
Generic 2 (Ferrer)	30/11/2016	01/07/2016	1.440	0.6	-40%	0%
Generic 3 (Fresenius)	31/12/2016	22/07/2016	1.440	0.7	-40%	0%
Generic 4 (Ranxaby)	31/07/2017	17/04/2017	1.440	1.3	-40%	0%
Generic 5 (Prasfarma)	31/12/2017	01/06/2017	1.440	1.7	-40%	0%
Generic 6 (Krka)	30/11/2019	22/05/2018	1.440	3.6	-40%	0%
Generic 7 (Accord)	30/09/2020	18/01/2016	1.332	4.4	-45%	-7%
Generic 8 (Fresenius)	31/01/2021	10/06/2020	1.332	4.8	-45%	-7%

* In the case of the innovative drug, the authorized LP at the time of marketing of the first generic drug is indicated.

Table S VI. Analysis of the evolution of the LP of the different generic Erlotinib medicines approved in Spain with respect to the innovative drug.

Drug type & company	CIPM approval date	Marketing authorization date	CIPM LP (€/mg)*	Interval since 1st Gx approval by CIPM (years)	Price difference vs innovative price	Price difference vs 1st Gx approved by CIPM
Innovative (Roche)	25/05/2007	19/09/2005	0.553	NA	NA	NA
Generic 1 (Teva)	25/04/2019	24/07/2018	0.319	0	-42%	NA
Generic 2 (Hetero)	29/02/2020	21/09/2018	0.319	0.8	-42%	0%
Generic 3 (Cipla)	31/05/2020	09/01/2020	0.143	1.1	-74%	-55%

* In the case of the innovative drug, the authorized LP at the time of marketing of the first generic drug is indicated.

Table S VII. Analysis of the evolution of the LP of the different generic Dasatinib medicines approved in Spain with respect to the innovative drug.

Drug type & company	CIPM approval date	Marketing authorization date	CIPM LP (€/mg)*	Interval since 1st Gx approval by CIPM (years)	Price difference vs innovative price	Price difference vs 1st Gx approved by CIPM
Innovative (BMS)	07/02/2009	NA	1.559	NA	NA	NA
Generic 1 (Teva)	30/10/2019	01/05/2019	0.49	0	-69%	0%
Generic 2 (Stada)	28/02/2021	01/07/2020	0.472	1.3	-70%	-4%

* In the case of the innovative medicine, the authorized PVL at the time of marketing of the first generic drug is indicated.

Table S VIII. Analysis of the evolution of the LP of the different generic Gefitinib medicines approved in Spain with respect to the innovative drug.

Drug type & company	CIPM approval date	Marketing authorization date	CIPM LP (€/mg)*	Interval since 1st Gx approval by CIPM (years)	Price difference vs innovative price	Price difference vs 1st Gx approved by CIPM
Innovative (AstraZeneca)	01/02/2010	24/06/2009	0.273	NA	NA	NA
Generic 1 (Accord)	30/06/2019	28/03/2019	0.164	0	-40%	NA
Generic 2 (Aristo)	30/06/2019	19/11/2018	0.164	0	-40%	0%
Generic 3 (Mylan)	30/06/2019	02/01/2019	0.164	0	-40%	0%
Generic 4 (Reig Jofre)	30/06/2019	08/02/2019	0.164	0	-40%	0%
Generic 5 (Sandoz)	30/06/2019	28/12/2018	0.164	0	-40%	0%
Generic 6 (Teva)	30/06/2019	21/02/2019	0.164	0	-40%	0%
Generic 7 (Qilu)	31/08/2019	08/04/2019	0.164	0.2	-40%	0%
Generic 8 (Cipla)	31/07/2020	14/01/2020	0.043	1.1	-84%	-74%

* In the case of the innovative medicine, the authorized LP at the time of marketing of the first generic drug is indicated.

Tabla S IX. Analysis of the evolution of the LP of the different generic Everolimus medicines approved in Spain with respect to the innovative drug.

Drug type & company	CIPM approval date	Marketing authorization date	CIPM LP (€/mg)*	Interval since 1st Gx approval by CIPM (years)	Price difference vs innovative price	Price difference vs 1st Gx approved by CIPM
Innovative (Novartis)	08/07/2010	17/09/2009	16.89	NA	NA	NA
Generic 1 (Stada)	30/11/2018	01/07/2018	7.094	0	-58%	NA
Generic 2 (Accord)	28/02/2019	01/10/2018	7.094	0.2	-58%	0%
Generic 3 (Krka)	28/02/2019	01/10/2018	7.094	0.2	-58%	0%
Generic 4 (Reddy Pharma)	28/02/2019	01/09/2018	7.094	0.2	-58%	0%
Generic 5 (Sandoz)	30/06/2019	01/03/2019	7.094	0.6	-58%	0%
Generic 6 (Tamarang)	29/02/2020	01/05/2019	5.777	1.2	-66%	-19%
Generic 7 (Mylan)	31/05/2020	09/01/2020	5.777	1.5	-66%	-19%
Generic 8 (Medicare)	31/07/2020	19/09/2019	5.777	1.7	-66%	-19%

* In the case of the innovative medicine, the authorized LP at the time of marketing of the first generic drug is indicated.

Public tender data

Table S X. Tenders identified for the Capecitabine drug between years 2012 and 2016.

ORGANISM		BATCH DATA			AWARD DATA		
Region	Convening body	Product requested by the agency	Volume for tender's duration (mg)	Maximum bid price (€/mg)	Awardee	Award price (€/mg)	Award date
Madrid	Servicio Madrileño de Salud	Capecitabina	1,334,512,000	0.0004	ACCORD HEALTHCARE	0.0004	27/03/2017
Madrid	Servicio Madrileño de Salud	Capecitabina	1,334,512,000	0.0004	CIPLA EUROPE	0.0004	27/03/2017
Baleares	Servicio de Salud de las Islas Baleares	Capecitabina 500mg comprimidos	225,000,000	0.0004	ACCORD HEALTHCARE	0.0004	26/07/2017
Baleares	Servicio de Salud de las Islas Baleares	Capecitabina 500mg comprimidos	225,000,000	0.0004	CIPLA EUROPE	0.0004	26/07/2017
Cataluña	Consorci de Salut i Atenció Social de Catalunya	CAPECITABINA 150 MG 60 COMPRIMIDOS CUBIERTA PELICULAR	42,939,300	0.0005	ACCORD HEALTHCARE	0.0005	10/07/2018
Cataluña	Consorci de Salut i Atenció Social de Catalunya	CAPECITABINA 150 MG 60 COMPRIMIDOS CUBIERTA PELICULAR	42,939,300	0.0005	CIPLA EUROPE	0.0005	10/07/2018
Cataluña	Consorci de Salut i Atenció Social de Catalunya	CAPECITABINA 150 MG 60 COMPRIMIDOS CUBIERTA PELICULAR	42,939,300	0.0005	LABORATORIOS NORMON	0.0005	10/07/2018
Cataluña	Consorci de Salut i Atenció Social de Catalunya	CAPECITABINA 500 MG 120 COMPRIMIDOS CUBIERTA PELICULAR	754,828,000	0.0004	ACCORD HEALTHCARE	0.0004	10/07/2018
Cataluña	Consorci de Salut i Atenció Social de Catalunya	CAPECITABINA 500 MG 120 COMPRIMIDOS CUBIERTA PELICULAR	754,828,000	0.0004	CIPLA EUROPE	0.0004	10/07/2018
Cataluña	Consorci de Salut i Atenció Social de Catalunya	CAPECITABINA 500 MG 120 COMPRIMIDOS CUBIERTA PELICULAR	754,828,000	0.0004	LABORATORIOS NORMON	0.0004	10/07/2018
Canarias	Servicio Canario de la Salud	CAPECITABINA - CAPECITABINA 150 MG COMPRIMIDOS ORAL	12,699,000	0.0005	CIPLA EUROPE	0.0004	10/08/2018
Canarias	Servicio Canario de la Salud	CAPECITABINA - CAPECITABINA 500 MG COMPRIMIDOS ORAL	197,400,000	0.0004	CIPLA EUROPE	0.0004	10/08/2018
Comunidad Valenciana	Generalitat Valenciana. Conselleria de Sanidad Universal y Salud Pública	Capecitabina 500 COMPRIMIDOS	939,110,000	0.0004	ACCORD HEALTHCARE	0.0004	28/03/2019
Andalucía	Plataforma de Logística Sanitaria de Granada	CAPECITABINA 500MG, COMPRIMIDOS	81,300,000	0.0004	CIPLA EUROPE	0.0004	24/04/2019
Murcia	Servicio Murciano de Salud	CAPECITABINA ORAL	378,996,000	0.0004	CIPLA EUROPE	0.0004	28/08/2019
Extremadura	Servicio Extremeño de Salud	Capecitabina 500mg 1 Comprimido	200,579,500	0.0004	ACCORD HEALTHCARE	0.0004	16/10/2019
Galicia	Servicio Gallego de Salud	Capecitabina (D.O.E.) oral	869,200,000	0.0004	CIPLA EUROPE	0.0004	20/11/2019
Andalucía	Plataforma de Logística Sanitaria de Jaén	CAPECITABINA 500MG, COMPRIMIDOS	26,000,000	0.0006	CIPLA EUROPE	0.0004	12/03/2020
Cataluña	Institut Català de la Salut (ICS)	CAPECITABINA 150 mg comp	2,254,500	0.0005	KERN PHARMA	0.0005	22/06/2020
Cataluña	Institut Català de la Salut (ICS)	CAPECITABINA 500 mg comp	60,930,000	0.0004	KERN PHARMA	0.0004	22/06/2020
Pais Vasco	Osakidetza-S.v.s.	CAPECITABINA (DOE) COMPRIMIDO DE 150MG	10,950,000	0.0005	KERN PHARMA	0.0005	26/11/2020
Pais Vasco	Osakidetza-S.v.s.	CAPECITABINA (DOE) COMPRIMIDO DE 500MG	185,000,000	0.0004	KERN PHARMA	0.0004	26/11/2020
Pais Vasco	Osakidetza-S.v.s.	CAPECITABINA (DOE) COMPRIMIDO DE 300MG	9,000,000	0.0004	KERN PHARMA	0.0004	26/11/2020
Andalucía	Plataforma de Logística Sanitaria de Huelva	CAPECITABINA 500MG, COMPRIMIDOS	78,240,000	0.0006	LABORATORIOS NORMON	0.0004	30/12/2020
Asturias	Servicio de Salud del Principado de Asturias (Sespa)	CAPECITABINA CAPSULA/COMPRIMIDO	228,730,000	0.0008	KERN PHARMA	0.0005	03/03/2021
Navarra	Servicio Navarro de Salud - Osasunbidea	Capecitabina 150 mg comprimidos	7,389,000	0.0005	KERN PHARMA	0.0005	30/03/2021
Navarra	Servicio Navarro de Salud - Osasunbidea	Capecitabina 500 mg comprimidos	72,780,000	0.0004	KERN PHARMA	0.0004	30/03/2021

Table S XI. Tenders identified for the Imatinib drug between years 2017 and 2021.

ORGANISM		BATCH DATA			AWARD DATA		
Region	Convening body	Product requested by the agency	Volume for tender's duration (mg)	Maximum bid price (€/ mg)	Awardee	Award price (€/mg)	Award date
Navarra	Servicio Navarro de Salud - Osasunbidea	Imatinib 100 mg.	178,300	0.0987	NOVARTIS FARMACEUTICA	0.0907	30/06/2017
Navarra	Servicio Navarro de Salud - Osasunbidea	Imatinib 400 mg.	1,353,600	0.0986	NOVARTIS FARMACEUTICA	0.0907	30/06/2017
Navarra	Servicio Navarro de Salud - Osasunbidea	Imatinib 100 mg	713,300	0.0058	CIPLA EUROPE	0.0014	30/06/2017
Navarra	Servicio Navarro de Salud - Osasunbidea	Imatinib 400 mg	5,415,200	0.0057	CIPLA EUROPE	0.0014	30/06/2017
Murcia	Servicio Murciano de Salud	IMATINIB 100 MG COMPRIMIDOS RECUBIERTOS/CAPSULAS	4,200,000	0.0075	ACCORD HEALTHCARE	0.0016	18/02/2018
Murcia	Servicio Murciano de Salud	IMATINIB 400 MG COMPRIMIDOS RECUBIERTOS/CAPSULAS	14,280,000	0.0075	ACCORD HEALTHCARE	0.0015	18/02/2018
Cataluña	Consorti de Salut i Atenció Social de Catalunya	IMATINIB 400 MG 30 COMPRIMIDOS/CAPSULAS	24,015,200	0.1184	ACCORD HEALTHCARE	0.0015	10/07/2018
Cataluña	Consorti de Salut i Atenció Social de Catalunya	IMATINIB 400 MG 30 COMPRIMIDOS/CAPSULAS	24,015,200	0.1184	CIPLA EUROPE	0.0013	10/07/2018
Cataluña	Consorti de Salut i Atenció Social de Catalunya	IMATINIB 400 MG 30 COMPRIMIDOS/CAPSULAS	24,015,200	0.1184	KERN PHARMA	0.0031	10/07/2018
Cataluña	Consorti de Salut i Atenció Social de Catalunya	IMATINIB 100 MG 60 COMPRIMIDOS/CAPSULAS	2,823,600	0.1184	ACCORD HEALTHCARE	0.0026	10/07/2018
Cataluña	Consorti de Salut i Atenció Social de Catalunya	IMATINIB 100 MG 60 COMPRIMIDOS/CAPSULAS	2,823,600	0.1184	CIPLA EUROPE	0.0012	10/07/2018
Cataluña	Consorti de Salut i Atenció Social de Catalunya	IMATINIB 100 MG 60 COMPRIMIDOS/CAPSULAS	2,823,600	0.1184	KERN PHARMA	0.0015	10/07/2018
Cataluña	Consorti de Salut i Atenció Social de Catalunya	IMATINIB 100 MG COM (indicació GIST)	1,400,400	0.0544	NOVARTIS FARMACEUTICA	0.0544	10/07/2018
Cataluña	Consorti de Salut i Atenció Social de Catalunya	IMATINIB 400 MG COM (indicació GIST)	22,269,600	0.0544	NOVARTIS FARMACEUTICA	0.0544	10/07/2018
Andalucía	Plataforma de Logística Sanitaria de Córdoba	IMATINIB 100MG, COMPRIMIDOS-Forma farmacéutica:COMPRIMIDOS	2,200,000	0.0055	ACCORD HEALTHCARE	0.0016	26/07/2018
Andalucía	Plataforma de Logística Sanitaria de Córdoba	IMATINIB 400MG, COMPRIMIDOS-Forma farmacéutica:COMPRIMIDOS	21,600,000	0.0058	ACCORD HEALTHCARE	0.0013	26/07/2018
Madrid	Hospital Clínico San Carlos	GLIVEC 100 MG	540,000	0.0566	NOVARTIS FARMACEUTICA	0.0544	30/07/2018
Madrid	Hospital Clínico San Carlos	GLIVEC 400 MG	3,120,000	0.0566	NOVARTIS FARMACEUTICA	0.0544	30/07/2018
Canarias	Servicio Canario de la Salud	IMATINIB - IMATINIB 400 MG 30 CÁPSULAS	19,480,000	0.1184	CIPLA EUROPE	0.0015	10/08/2018
Canarias	Servicio Canario de la Salud	IMATINIB - IMATINIB 100 MG 60 CÁPSULAS	2,650,000	0.1184	CIPLA EUROPE	0.0015	10/08/2018
Cataluña	Institut Català de la Salut (ICS)	IMATINIB 100 mg comp (EFG)	2,616,000	0.0015	ACCORD HEALTHCARE	0.0014	12/12/2018
Cataluña	Institut Català de la Salut (ICS)	IMATINIB 400 mg comp (EFG)	12,120,000	0.0015	ACCORD HEALTHCARE	0.0014	12/12/2018
Comunidad Valenciana	Generalitat Valenciana. Conselleria de Sanidad Universal y Salud Pública	Imatinib 100 MG COMPRIMIDOS, CÁPSULAS	16,568,000	0.0090	ACCORD HEALTHCARE	0.0021	20/02/2019
Comunidad Valenciana	Generalitat Valenciana. Conselleria de Sanidad Universal y Salud Pública	Imatinib 100 MG COMPRIMIDOS, CÁPSULAS	16,568,000	0.0090	CIPLA EUROPE	0.0035	20/02/2019
Comunidad Valenciana	Generalitat Valenciana. Conselleria de Sanidad Universal y Salud Pública	Imatinib 100 MG COMPRIMIDOS, CÁPSULAS	16,568,000	0.0090	SANDOZ FARMACEUTICA	0.0089	20/02/2019
Comunidad Valenciana	Generalitat Valenciana. Conselleria de Sanidad Universal y Salud Pública	Imatinib 100 MG COMPRIMIDOS, CÁPSULAS	16,568,000	0.0090	TEVA PHARMA	0.0070	20/02/2019
Comunidad Valenciana	Generalitat Valenciana. Conselleria de Sanidad Universal y Salud Pública	Imatinib 400 MG COMPRIMIDOS, CÁPSULAS	76,275,200	0.0091	ACCORD HEALTHCARE	0.0025	20/02/2019
Comunidad Valenciana	Generalitat Valenciana. Conselleria de Sanidad Universal y Salud Pública	Imatinib 400 MG COMPRIMIDOS, CÁPSULAS	76,275,200	0.0091	CIPLA EUROPE	0.0029	20/02/2019
Comunidad Valenciana	Generalitat Valenciana. Conselleria de Sanidad Universal y Salud Pública	Imatinib 400 MG COMPRIMIDOS, CÁPSULAS	76,275,200	0.0091	KERN PHARMA	0.0088	20/02/2019
Comunidad Valenciana	Generalitat Valenciana. Conselleria de Sanidad Universal y Salud Pública	Imatinib 400 MG COMPRIMIDOS, CÁPSULAS	76,275,200	0.0091	SANDOZ FARMACEUTICA	0.0091	20/02/2019
Comunidad Valenciana	Generalitat Valenciana. Conselleria de Sanidad Universal y Salud Pública	Imatinib 400 MG COMPRIMIDOS, CÁPSULAS	76,275,200	0.0091	TEVA PHARMA	0.0050	20/02/2019
Murcia	Servicio Murciano de Salud	IMATINIB 100MG 60 COMPRIMIDOS RECUBIERTOS	3,000,000	0.0907	NOVARTIS FARMACEUTICA	0.0114	13/05/2019
Murcia	Servicio Murciano de Salud	IMATINIB 400MG 30 COMPRIMIDOS RECUBIERTOS	28,800,000	0.0906	NOVARTIS FARMACEUTICA	0.0114	13/05/2019
Andalucía	Plataforma de Logística Sanitaria de Granada	IMATINIB 100MG, COMPRIMIDOS	1,296,000	0.0024	CIPLA EUROPE	0.0012	31/05/2019
Madrid	Hospital Universitario de Getafe	IMATINIB 100 MG. COMP.	474,000	0.0066	TEVA PHARMA	0.0055	27/01/2020

Table S XI. Tenders identified for the Imatinib drug between years 2017 and 2021.

ORGANISM		BATCH DATA			AWARD DATA		
Region	Convening body	Product requested by the agency	Volume for tender's duration (mg)	Maximum bid price (€/ mg)	Awardee	Award price (€/mg)	Award date
Madrid	Hospital Universitario de Getafe	IMATINIB 400 MG. COMP.	4,020,000	0.0067	TEVA PHARMA	0.0014	27/01/2020
Andalucía	Plataforma de Logística Sanitaria de Jaén	IMATINIB 400MG, COMPRIMIDOS	1,400,000	0.0170	TEVA PHARMA	0.0013	12/03/2020
Asturias	Servicio de Salud del Principado de Asturias (Sespa)	IMATINIB 100 MG	1,438,000	0.0022	CIPLA EUROPE	0.0012	15/05/2020
Asturias	Servicio de Salud del Principado de Asturias (Sespa)	IMATINIB 400 MG	12,252,000	0.0022	CIPLA EUROPE	0.0012	15/05/2020
Cataluña	Institut Català d'Oncologia (ICO)	IMATINIB 100 mg comprimits/caps	4,140,000	0.0024	CIPLA EUROPE	0.0011	21/05/2020
Cataluña	Institut Català d'Oncologia (ICO)	IMATINIB 400 mg comprimits/caps	43,272,000	0.0015	CIPLA EUROPE	0.0011	21/05/2020
Asturias	Servicio de Salud del Principado de Asturias (Sespa)	GLIVEC 100 mg/60 comprimidos	432,000	0.0114	NOVARTIS FARMACEUTICA	0.0114	07/07/2020
Asturias	Servicio de Salud del Principado de Asturias (Sespa)	GLIVEC 400 mg/30 comprimidos	4,176,000	0.0114	NOVARTIS FARMACEUTICA	0.0114	07/07/2020
Cataluña	Consorci Hospital Clínic de Barcelona (HCB)	IMATINIB MESILATO 100 MG COMP o CAPS (generico)	3,438,600	0.0012	ACCORD HEALTHCARE	0.0011	16/12/2020
Cataluña	Consorci Hospital Clínic de Barcelona (HCB)	IMATINIB 100 MG COMP (original)	357,100	0.0114	NOVARTIS FARMACEUTICA	0.0114	16/12/2020
Cataluña	Consorci Hospital Clínic de Barcelona (HCB)	IMATINIB 400 MG COMP/CAPSULAS ORIGINAL	2,028,000	0.0114	NOVARTIS FARMACEUTICA	0.0114	16/12/2020
País Vasco	Osakidetza-S.v.s.	IMATINIB (DOE)	3,150,000	0.0114	NOVARTIS FARMACEUTICA	0.0058	16/03/2021
País Vasco	Osakidetza-S.v.s.	IMATINIB (DOE)	12,600,000	0.0114	NOVARTIS FARMACEUTICA	0.0058	16/03/2021
País Vasco	Osakidetza-S.v.s.	IMATINIB (DOE)	6,000,000	0.0040	ACCORD HEALTHCARE	0.0009	16/03/2021
País Vasco	Osakidetza-S.v.s.	IMATINIB (DOE)	24,000,000	0.0040	ACCORD HEALTHCARE	0.0012	16/03/2021
Andalucía	Plataforma de Logística Sanitaria de Sevilla	IMATINIB 400MG - ORAL	12,000,000	0.0012	ACCORD HEALTHCARE	0.0012	13/04/2021
Andalucía	Plataforma de Logística Sanitaria de Sevilla	IMATINIB 100MG - ORAL	2,500,000	0.0019	ACCORD HEALTHCARE	0.0010	13/04/2021

Table S XII. Tenders identified for the Erlotinib drug between years 2017 and 2021.

ORGANISM		BATCH DATA			AWARD DATA		
Region	Convening body	Product requested by the agency	Volume for tender's duration (mg)	Maximum bid price (€/mg)	Awardee	Award price (€/mg)	Award date
Extremadura	Servicio Extremeño de Salud	Erlotinib 100 mg comprimido	640,700	0.4914	ROCHE FARMA	0.4914	03/04/2017
Extremadura	Servicio Extremeño de Salud	Erlotinib 150 mg comprimido	774,450	0.4036	ROCHE FARMA	0.4036	03/04/2017
Asturias	Gerencia Atención Sanitaria Área IV - Hospital Universitario Central de Asturias	ERLOTINIB 100MG 30 COMP	72,000	0.4914	ROCHE FARMA	0.4914	13/06/2017
Asturias	Gerencia Atención Sanitaria Área IV - Hospital Universitario Central de Asturias	ERLOTINIB 150MG 30 COMP	108,000	0.4036	ROCHE FARMA	0.4036	13/06/2017
Castilla la Mancha	Gerencia de Atención Integrada de Albacete	ERLOTINIB 100 MG COMPRIMIDO	12,000	0.1442	ROCHE FARMA	0.1442	10/01/2019
Castilla la Mancha	Gerencia de Atención Integrada de Albacete	ERLOTINIB 150 MG COMPRIMIDO	100,800	0.3407	ROCHE FARMA	0.3407	10/01/2019
Comunidad Valenciana	Generalitat Valenciana. Conselleria de Sanidad Universal y Salud Pública	Erlotinib 25 MG COMPRIMIDOS	134,750	0.5540	ROCHE FARMA	0.5540	20/02/2019
Comunidad Valenciana	Generalitat Valenciana. Conselleria de Sanidad Universal y Salud Pública	Erlotinib 100 MG COMPRIMIDOS	1,080,000	0.4906	ROCHE FARMA	0.4906	20/02/2019
Comunidad Valenciana	Generalitat Valenciana. Conselleria de Sanidad Universal y Salud Pública	Erlotinib 150 MG COMPRIMIDOS	3,775,800	0.4030	ROCHE FARMA	0.4030	20/02/2019
Canarias	Servicio Canario de Salud	ERLOTINIB 100 MG COMPRIMIDOS ORAL C/30	90,000	0.4914	ROCHE FARMA	0.4668	30/04/2019
Canarias	Servicio Canario de Salud	ERLOTINIB 150 MG COMPRIMIDOS ORAL C/30	478,500	0.4036	ROCHE FARMA	0.3835	30/04/2019
Madrid	Hospital General Universitario Gregorio Marañón	ERLOTINIB 100 MG COMP. C/30	102,000	0.4914	ROCHE FARMA	0.4914	20/06/2019
Aragón	Servicio Aragonés de Salud	TARCEVA (ERLOTINIB)100 MG COMPRIMIDOS RECUBIERTOS	900,000	0.6325	ROCHE FARMA	0.5312	01/10/2019
Aragón	Servicio Aragonés de Salud	TARCEVA (ERLOTINIB)150 MG COMPRIMIDOS RECUBIERTOS	450,000	0.6325	ROCHE FARMA	0.4363	01/10/2019
Aragón	Servicio Aragonés de Salud	TARCEVA (ERLOTINIB)25 MG COMPRIMIDOS RECUBIERTOS	60,000	0.6325	ROCHE FARMA	0.6000	01/10/2019
Andalucía	Plataforma de Logística Sanitaria de Sevilla	ERLOTINIB 150MG, COMPRIMIDOS	354,000	0.4036	ROCHE FARMA	0.4036	18/10/2019
Castilla y León	Gerencia Regional de Salud de Castilla y León	ERLOTINIB COMPRIMIDOS ORAL 25 MG	34,500	0.5550	ROCHE FARMA	0.5550	30/12/2019
Castilla y León	Gerencia Regional de Salud de Castilla y León	ERLOTINIB COMPRIMIDOS ORAL 100 MG	834,000	0.4914	ROCHE FARMA	0.4914	30/12/2019
Castilla y León	Gerencia Regional de Salud de Castilla y León	ERLOTINIB COMPRIMIDOS ORAL 150 MG	963,000	0.4036	ROCHE FARMA	0.4036	30/12/2019
Murcia	Servicio Murciano de Salud	ERLOTINIB 100MG 30 COMPRIMIDOS RECUBIERTOS	840,000	0.4914	ROCHE FARMA	0.4914	11/01/2020
Murcia	Servicio Murciano de Salud	ERLOTINIB 150MG 30 COMPRIMIDOS RECUBIERTOS	2,070,000	0.4036	ROCHE FARMA	0.4036	11/01/2020
Murcia	Servicio Murciano de Salud	ERLOTINIB 25MG 30 COMPRIMIDOS RECUBIERTOS	180,000	0.5550	ROCHE FARMA	0.5550	11/01/2020
Madrid	Hospital Universitario la Paz	ERLOTINIB - TARCEVA 100mg compr C/30 - CN 652160	150,000	0.4914	ROCHE FARMA	0.4914	10/02/2020
Madrid	Hospital Universitario la Paz	ERLOTINIB - TARCEVA 150mg comp C/30 - CN 652161	630,000	0.4036	ROCHE FARMA	0.4036	10/02/2020
Cataluña	Institut Català de la Salut (ICS)	ERLOTINIB 150 mg comp	51,750	0.4036	SANDOZ FARMACEUTICA	0.0288	23/09/2020
Cataluña	Institut Català de la Salut (ICS)	ERLOTINIB 100 mg comp	33,000	0.4914	SANDOZ FARMACEUTICA	0.0351	23/09/2020
Andalucía	Plataforma de Logística Sanitaria de Córdoba	ERLOTINIB 150MG, COMPRIMIDOS	240,000	0.1282	TEVA PHARMA	0.0333	24/09/2020
Madrid	Hospital Universitario Puerta de Hierro	ERLOTINIB 25 MG COMPR	3,000	0.1800	SANDOZ FARMACEUTICA	0.0900	11/11/2020
Madrid	Hospital Universitario Puerta de Hierro	ERLOTINIB 100 MG COMPR	510,000	0.1867	SANDOZ FARMACEUTICA	0.0349	11/11/2020
Madrid	Hospital Universitario Puerta de Hierro	ERLOTINIB 150 MG COMPR	375,000	0.0999	SANDOZ FARMACEUTICA	0.0286	11/11/2020
Pais Vasco	Osakidetza-S.v.s.	ERLOTINIB (DOE) COMPRIMIDO DE 100MG	240,000	0.1597	SANDOZ FARMACEUTICA	0.0350	26/11/2020
Pais Vasco	Osakidetza-S.v.s.	ERLOTINIB (DOE) COMPRIMIDO DE 150MG	390,000	0.1311	SANDOZ FARMACEUTICA	0.0287	26/11/2020
Cataluña	Consorci Hospital Clínic de Barcelona (HCB)	ERLOTINIB 150 MG COMP REC PELIC	101,700	0.4036	TARBIS FARMA	0.0400	16/12/2020
Cataluña	Consorci de Salut i Atenció Social de Catalunya	ERLOTINIB 100 MG COMPRIMIDO	1,749,400	0.3187	ROCHE FARMA	0.3187	29/12/2020
Cataluña	Consorci de Salut i Atenció Social de Catalunya	ERLOTINIB 100 MG COMPRIMIDO	1,749,400	0.3187	SANDOZ FARMACEUTICA	0.0317	29/12/2020
Cataluña	Consorci de Salut i Atenció Social de Catalunya	ERLOTINIB 100 MG COMPRIMIDO	1,749,400	0.3187	TARBIS FARMA	0.0298	29/12/2020
Cataluña	Consorci de Salut i Atenció Social de Catalunya	ERLOTINIB 100 MG COMPRIMIDO	1,749,400	0.3187	TEVA PHARMA	0.3187	29/12/2020

Table S XII. Tenders identified for the Erlotinib drug between years 2017 and 2021.

ORGANISM		BATCH DATA			AWARD DATA		
Region	Convening body	Product requested by the agency	Volume for tender's duration (mg)	Maximum bid price (€/ mg)	Awardee	Award price (€/mg)	Award date
Cataluña	Consorci de Salut i Atenció Social de Catalunya	ERLOTINIB 150 MG COMPRIMIDO	2,415,600	0.2618	ROCHE FARMA	0.2618	29/12/2020
Cataluña	Consorci de Salut i Atenció Social de Catalunya	ERLOTINIB 150 MG COMPRIMIDO	2,415,600	0.2618	SANDOZ FARMACEUTICA	0.0286	29/12/2020
Cataluña	Consorci de Salut i Atenció Social de Catalunya	ERLOTINIB 150 MG COMPRIMIDO	2,415,600	0.2618	TARBIS FARMA	0.0212	29/12/2020
Cataluña	Consorci de Salut i Atenció Social de Catalunya	ERLOTINIB 150 MG COMPRIMIDO	2,415,600	0.2618	TEVA PHARMA	0.2618	29/12/2020
Cataluña	Consorci de Salut i Atenció Social de Catalunya	ERLOTINIB 25 MG COMPRIMIDO	365,550	0.3600	ROCHE FARMA	0.3600	29/12/2020
Cataluña	Consorci de Salut i Atenció Social de Catalunya	ERLOTINIB 25 MG COMPRIMIDO	365,550	0.3600	SANDOZ FARMACEUTICA	0.0716	29/12/2020
Cataluña	Consorci de Salut i Atenció Social de Catalunya	ERLOTINIB 25 MG COMPRIMIDO	365,550	0.3600	TARBIS FARMA	0.0392	29/12/2020
Cataluña	Consorci de Salut i Atenció Social de Catalunya	ERLOTINIB 25 MG COMPRIMIDO	365,550	0.3600	TEVA PHARMA	0.0392	29/12/2020
Cataluña	Institut Català d'Oncologia (ICO)	ERLOTINIB 25 MG	187,500	0.0424	TARBIS FARMA	0.0240	10/02/2021
Cataluña	Institut Català d'Oncologia (ICO)	ERLOTINIB 100 MG	435,000	0.0356	TARBIS FARMA	0.0218	10/02/2021
Cataluña	Institut Català d'Oncologia (ICO)	ERLOTINIB 150 MG	742,500	0.0289	TARBIS FARMA	0.0162	10/02/2021

Table S XIII. Tenders identified for the Gefitinib drug between years 2018 and 2021.

ORGANISM		BATCH DATA			AWARD DATA		
Region	Convening body	Product requested by the agency	Volume for tender's duration (mg)	Maximum bid price (€/mg)	Awardee	Award price (€/mg)	Award date
Madrid	Hospital General Universitario Gregorio Marañón	GEFITINIB (IRESSA) 250 MG 30 COMPRIMIDOS RECUBIERTOS	547,500	0.2422	ASTRAZENECA FARMACEUTICA SPAIN	0.2422	17/05/2018
Madrid	Hospital Clínico San Carlos	GEFITINIB (IRESSA) 250 MG COMP	600,000	0.2422	ASTRAZENECA FARMACEUTICA SPAIN	0.2422	07/06/2018
Castilla la Mancha	Gerencia de Atención Integrada de Almansa	GEFITINIB - IRESSA 250 MG COMP E/30	360,000	0.2523	ASTRAZENECA FARMACEUTICA SPAIN	0.2523	22/01/2019
Canarias	Servicio Canario de Salud	GEFITINIB 250 MG COMPRIMIDOS ORAL C/30	1,142,500	0.2523	ASTRAZENECA FARMACEUTICA SPAIN	0.2523	30/04/2019
Murcia	Servicio Murciano de Salud	GEFITINIB 250 MG 30 COMPRIMIDOS RECUBIERTOS	3,000,000	0.2523	ASTRAZENECA FARMACEUTICA SPAIN	0.2523	13/05/2019
Andalucía	Plataforma de Logística Sanitaria de Jaén	GEFITINIB 250MG COMPRIMIDOS-Forma farmacéutica:COMPRIMIDOS	812,500	0.2422	ASTRAZENECA FARMACEUTICA SPAIN	0.2422	03/07/2019
Pais Vasco	Osakidetza-S.v.s.	GEFITINIB COMPRIMIDO DE 250MG	1,250,000	0.0187	TEVA PHARMA	0.0120	11/09/2019
Asturias	Servicio de Salud del Principado de Asturias (Sespa)	GEFITINIB 250 MG. COMPRIMIDOS RECUBIERTOS CON PELICULA	937,500	0.0240	ACCORD HEALTHCARE	0.0091	05/06/2020
Asturias	Servicio de Salud del Principado de Asturias (Sespa)	GEFITINIB 250 MG. COMPRIMIDOS RECUBIERTOS CON PELICULA	1,260,000	0.0240	ACCORD HEALTHCARE	0.0091	05/06/2020
Cataluña	Institut Català de la Salut (ICS)	GEFITINIB 250 mg comp	399,375	0.2523	ACCORD HEALTHCARE	0.0078	22/06/2020
Andalucía	Plataforma de Logística Sanitaria de Córdoba	GEFITINIB 250MG. COMPRIMIDOS-Forma farmacéutica:COMPRIMIDOS	1,300,000	0.0202	TEVA PHARMA	0.0060	24/09/2020
Cataluña	Consorci de Salut i Atenció Social de Catalunya	GEFITINIB 250 MG COMPRIMIDOS RECUBIERTO	1,957,000	0.1600	ACCORD HEALTHCARE	0.0077	29/12/2020
Cataluña	Consorci de Salut i Atenció Social de Catalunya	GEFITINIB 250 MG COMPRIMIDOS RECUBIERTO	1,957,000	0.1600	CIPLA EUROPE	0.0090	29/12/2020
Cataluña	Consorci de Salut i Atenció Social de Catalunya	GEFITINIB 250 MG COMPRIMIDOS RECUBIERTO	1,957,000	0.1600	LABORATORIO REIG JOFRE	0.0062	29/12/2020
Cataluña	Consorci de Salut i Atenció Social de Catalunya	GEFITINIB 250 MG COMPRIMIDOS RECUBIERTO	1,957,000	0.1600	SANDOZ FARMACEUTICA	0.0104	29/12/2020
Cataluña	Corporació Sanitària Parc Taulí	GEFITINIB 250 MG COMP - GEFITINIB	240,500	0.0200	TEVA PHARMA	0.0080	26/01/2021

Table S XIV. Tenders identified for the Everolimus drug between years 2017 and 2021.

ORGANISM		BATCH DATA			AWARD DATA		
Region	Convening body	Product requested by the agency	Volume for tender's duration (mg)	Maximum bid price (€/ mg)	Awardee	Award price (€/mg)	Award date
Castilla y León	Complejo Asistencial Universitario de Salamanca	AFINITOR 5 mg 30 COMP.	5,250	10.9365	NOVARTIS FARMACEUTICA	10.9365	04/08/2017
Castilla y León	Complejo Asistencial Universitario de Salamanca	AFINITOR 10 mg 30 COMP.	27,000	8.9057	NOVARTIS FARMACEUTICA	8.9057	04/08/2017
Asturias	Gerencia Atención Sanitaria Área IV - Hospital Universitario Central de Asturias	Everolimus 0,25 mg (60 comp.) (Certican)	225	6.1240	NOVARTIS FARMACEUTICA	6.1240	08/01/2019
Asturias	Gerencia Atención Sanitaria Área IV - Hospital Universitario Central de Asturias	Everolimus 0,5 mg (60 comp.) (Certican)	60	6.1240	NOVARTIS FARMACEUTICA	6.1240	08/01/2019
Asturias	Gerencia Atención Sanitaria Área IV - Hospital Universitario Central de Asturias	Everolimus 1 mg (60 com p.) (Certican)	840	6.1242	NOVARTIS FARMACEUTICA	6.1242	08/01/2019
Asturias	Gerencia Atención Sanitaria Área IV - Hospital Universitario Central de Asturias	Everolimus 5 mg (30 comp.) (Afinitor)	15,900	10.9365	NOVARTIS FARMACEUTICA	10.9365	08/01/2019
Asturias	Gerencia Atención Sanitaria Área IV - Hospital Universitario Central de Asturias	Everolimus 10 mg (30 comp.) (Afinitor)	36,600	8.9057	NOVARTIS FARMACEUTICA	8.9057	08/01/2019
Asturias	Gerencia Atención Sanitaria Área IV - Hospital Universitario Central de Asturias	Everolimus 3 mg (30 comp.) (Votubia)	1,980	9.0773	NOVARTIS FARMACEUTICA	9.0773	08/01/2019
Asturias	Gerencia Atención Sanitaria Área IV - Hospital Universitario Central de Asturias	Everolimus 5 mg (30 comp.) (Votubia)	1,500	9.0777	NOVARTIS FARMACEUTICA	9.0777	08/01/2019
Andalucía	Plataforma de Logística Sanitaria de Sevilla	EVEROLIMUS 10MG, COMPRIMIDOS-Forma	124,500	8.9057	NOVARTIS FARMACEUTICA	8.9057	13/02/2019
Andalucía	Plataforma de Logística Sanitaria de Sevilla	EVEROLIMUS 500MCG, COMPRIMIDOS-Forma	785	6.1241	NOVARTIS FARMACEUTICA	6.1241	13/02/2019
Andalucía	Plataforma de Logística Sanitaria de Sevilla	EVEROLIMUS 750MCG, COMPRIMIDOS-Forma	2,355	6.1241	NOVARTIS FARMACEUTICA	6.1241	13/02/2019
Comunidad Valenciana	Generalitat Valenciana. Conselleria de Sanidad Universal y Salud Pública	Everolimus 5 MG COMPRIMIDOS (HUERFANO)	40,200	9.0640	NOVARTIS FARMACEUTICA	9.0640	28/03/2019
Comunidad Valenciana	Generalitat Valenciana. Conselleria de Sanidad Universal y Salud Pública	Everolimus 10 MG COMPRIMIDOS	374,920	8.8920	NOVARTIS FARMACEUTICA	8.8920	28/03/2019
Comunidad Valenciana	Generalitat Valenciana. Conselleria de Sanidad Universal y Salud Pública	Everolimus 10 MG COMPRIMIDOS (HUERFANO)	4,800	8.8920	NOVARTIS FARMACEUTICA	8.8920	28/03/2019
Comunidad Valenciana	Generalitat Valenciana. Conselleria de Sanidad Universal y Salud Pública	Everolimus 2.5 MG COMPRIMIDOS (HUERFANO)	23,700	9.0640	NOVARTIS FARMACEUTICA	9.0640	28/03/2019
Cataluña	Institut Català de la Salut (ICS)	A-EVEROLIMUS 5 mg comp	5,775	10.9365	ACCORD HEALTHCARE	2.6900	27/06/2019
Cataluña	Institut Català de la Salut (ICS)	A-EVEROLIMUS 10 mg comp	32,550	8.9057	ACCORD HEALTHCARE	2.2200	27/06/2019
Extremadura	Servicio Extremeño de Salud	Everolimus (AFINITOR) 10 Mg 1 Comprimido	51,900	8.9058	ACCORD HEALTHCARE	4.7000	16/10/2019
Extremadura	Servicio Extremeño de Salud	Everolimus (AFINITOR) 5 Mg 1 Comprimido	20,400	10.9365	ACCORD HEALTHCARE	4.8400	16/10/2019
Murcia	Servicio Murciano de Salud	AFINITOR 10MG COMPRIMIDOS, 30 COMPRIMIDOS-663793	-	8.9057	NOVARTIS FARMACEUTICA	5.7767	28/11/2019
Murcia	Servicio Murciano de Salud	AFINITOR 5MG COMPRIMIDOS, 30 COMPRIMIDOS-663792	-	10.9365	NOVARTIS FARMACEUTICA	5.7767	28/11/2019
Murcia	Servicio Murciano de Salud	CERTICAN 1 MG COMPRIMIDOS, 60 COMPRIMIDOS-700530	-	5.6275	NOVARTIS FARMACEUTICA	5.6275	28/11/2019
Murcia	Servicio Murciano de Salud	CERTICAN 0,75 MG COMPRIMIDOS, 60 COMPRIMIDOS-700529	-	5.6276	NOVARTIS FARMACEUTICA	5.6276	28/11/2019
Murcia	Servicio Murciano de Salud	CERTICAN 0,5 MG COMPRIMIDOS, 60 COMPRIMIDOS-700528	-	5.6277	NOVARTIS FARMACEUTICA	5.6277	28/11/2019
Murcia	Servicio Murciano de Salud	VOTUBIA 10MG COMPRIMIDOS, 30 COMPRIMIDOS-697856	-	9.0778	NOVARTIS FARMACEUTICA	5.7767	28/11/2019
Murcia	Servicio Murciano de Salud	VOTUBIA 5MG COMPRIMIDOS, 30 COMPRIMIDOS-684617	-	9.0777	NOVARTIS FARMACEUTICA	5.7767	28/11/2019
Murcia	Servicio Murciano de Salud	VOTUBIA 2,5MG COMPRIMIDOS, 30 COMPRIMIDOS-684619	-	9.0777	NOVARTIS FARMACEUTICA	5.7767	28/11/2019
Andalucía	Plataforma de Logística Sanitaria de Córdoba	EVEROLIMUS 2MG, COMPRIMIDOS-Forma farmacéutica:COMPRIMIDOS	2,400	9.4560	NOVARTIS FARMACEUTICA	5.7767	19/12/2019
Andalucía	Plataforma de Logística Sanitaria de Córdoba	EVEROLIMUS 5MG, COMPRIMIDOS	7,500	9.4560	NOVARTIS FARMACEUTICA	5.7767	19/12/2019
Castilla la Mancha	Gerencia de Atención Integrada de Cuenca	VOTUBIA 5 mg comp c/30 - 684617	3,600	9.0920	NOVARTIS FARMACEUTICA	9.0778	13/01/2020
Madrid	Hospital Universitario Fundación Alcorcón	EVEROLIMUS - VOTUBIA 10 MG COMPRIMIDOS 30 COMPRIMIDOS - 697856	7,500	5.7767	NOVARTIS FARMACEUTICA	5.7767	02/07/2020
Cataluña	Consorci Hospital Clínic de Barcelona (HCB)	EVEROLIMUS 1 MG COMP	3,304	5.6275	NOVARTIS FARMACEUTICA	5.6276	16/12/2020
Cataluña	Consorci Hospital Clínic de Barcelona (HCB)	EVEROLIMUS 5 MG COMP/COMP	1,160	5.7767	NOVARTIS FARMACEUTICA	5.7767	16/12/2020
Cataluña	Consorci Hospital Clínic de Barcelona (HCB)	EVEROLIMUS 10 MG COMP/COMP	8,660	5.7767	NOVARTIS FARMACEUTICA	5.7767	16/12/2020
Cataluña	Consorci de Salut i Atenció Social de Catalunya	EVEROLIMUS (ANTITUMORAL) 10 MG COMPRIMIDOS	218,220	5.7770	ACCORD HEALTHCARE	1.7600	29/12/2020
Cataluña	Consorci de Salut i Atenció Social de Catalunya	EVEROLIMUS (ANTITUMORAL) 10 MG COMPRIMIDOS	218,220	5.7770	MEDICARE PHARMA	1.6065	29/12/2020
Cataluña	Consorci de Salut i Atenció Social de Catalunya	EVEROLIMUS (ANTITUMORAL) 10 MG COMPRIMIDOS	218,220	5.7770	NOVARTIS FARMACEUTICA	5.7767	29/12/2020
Cataluña	Consorci de Salut i Atenció Social de Catalunya	EVEROLIMUS (ANTITUMORAL) 10 MG COMPRIMIDOS	218,220	5.7770	REDDY PHARMA IBERIA	1.6000	29/12/2020

Table S XIV. Tenders identified for the Everolimus drug between years 2017 and 2021.

ORGANISM		BATCH DATA			AWARD DATA		
Region	Convening body	Product requested by the agency	Volume for tender's duration (mg)	Maximum bid price (€/mg)	Awardee	Award price (€/mg)	Award date
Cataluña	Consorci de Salut i Atenció Social de Catalunya	EVEROLIMUS (ANTITUMORAL) 5 MG COMPRIMIDO	66,310	7.0940	ACCORD HEALTHCARE	2.0400	29/12/2020
Cataluña	Consorci de Salut i Atenció Social de Catalunya	EVEROLIMUS (ANTITUMORAL) 5 MG COMPRIMIDO	66,310	7.0940	MEDICARE PHARMA	1.4666	29/12/2020
Cataluña	Consorci de Salut i Atenció Social de Catalunya	EVEROLIMUS (ANTITUMORAL) 5 MG COMPRIMIDO	66,310	7.0940	NOVARTIS FARMACEUTICA	5.7767	29/12/2020
Cataluña	Consorci de Salut i Atenció Social de Catalunya	EVEROLIMUS (ANTITUMORAL) 5 MG COMPRIMIDO	66,310	7.0940	REDDY PHARMA IBERIA	1.4540	29/12/2020
Cataluña	Corporació Sanitària Parc Taulí	EVEROLIMUS 5 MG COMP. - EVEROLIMUS	2,655	5.7767	ACCORD HEALTHCARE	2.4000	12/01/2021
Canarias	Servicio Canario de la Salud	EVEROLIMUS 0.25 MG ORAL-CERTICAN 0,25MG 60 COMPRIMIDOS	2,430	5.6273	NOVARTIS FARMACEUTICA	5.6273	21/01/2021
Canarias	Servicio Canario de la Salud	EVEROLIMUS 0.5 MG ORAL-CERTICAN 0,5MG 60 COMPRIMIDOS	7,020	5.6277	NOVARTIS FARMACEUTICA	5.6277	21/01/2021
Canarias	Servicio Canario de la Salud	EVEROLIMUS 0.75 MG ORAL-CERTICAN 0,75MG 60 COMPRIMIDOS	3,510	5.6367	NOVARTIS FARMACEUTICA	5.6276	21/01/2021
Canarias	Servicio Canario de la Salud	EVEROLIMUS 1 MG ORAL-CERTICAN 1MG 60 COMPRIMIDOS	12,840	5.6275	NOVARTIS FARMACEUTICA	5.6275	21/01/2021
Madrid	Hospital Universitario Puerta de Hierro	CERTICAN - EVEROLIMUS 0,25 MG COMPR DISPERS - CN 700527	1,500	5.6276	NOVARTIS FARMACEUTICA	5.6276	09/02/2021
Madrid	Hospital Universitario Puerta de Hierro	CERTICAN - EVEROLIMUS 0,50 MG COMPR - CN 700528	4,000	5.6276	NOVARTIS FARMACEUTICA	5.6276	09/02/2021
Madrid	Hospital Universitario Puerta de Hierro	CERTICAN - EVEROLIMUS 0,75 MG COMPR - CN 700529	9,000	5.6276	NOVARTIS FARMACEUTICA	5.6276	09/02/2021
Madrid	Hospital Universitario Puerta de Hierro	CERTICAN - EVEROLIMUS 1 MG COMPR - CN 700530	46,000	5.6276	NOVARTIS FARMACEUTICA	5.6276	09/02/2021
Madrid	Hospital Universitario Puerta de Hierro	VOTUBIA - EVEROLIMUS 2,5 MG COMPR - CN 684619	4,000	5.7767	NOVARTIS FARMACEUTICA	5.7767	09/02/2021
Madrid	Hospital Universitario Puerta de Hierro	VOTUBIA - EVEROLIMUS 5 MG COMP DISPERS - CN 684617	21,000	5.7767	NOVARTIS FARMACEUTICA	5.7767	09/02/2021
Madrid	Hospital Universitario Puerta de Hierro	VOTUBIA - EVEROLIMUS 3 MG COMP DISPERS - CN 702016	3,000	5.7767	NOVARTIS FARMACEUTICA	5.7767	09/02/2021
País Vasco	Osakidetza-S.v.s.	EVEROLIMUS (DOE) COMPRIMIDO DE 5MG	20,000	3.4660	LABORATORIO STADA	1.3280	21/05/2021
País Vasco	Osakidetza-S.v.s.	EVEROLIMUS (DOE) COMPRIMIDO DE 10MG	56,000	3.4660	LABORATORIO STADA	1.3290	21/05/2021